Clearside Biomedical, Inc.

Clearside sells primarily to pharmaceutical and ophthalmology partners rather than to end patients directly. Its commercial model depends on licensing XIPERE and the SCS Microinjector to companies that can market and distribute in specific territories, while also pursuing collaborations for new eye-disease candidates. The company’s direct customer base is therefore a mix of licensees, collaborators and, to a limited extent, approved-product purchasers of Microinjector kits.

Clearside’s near-term strategy is to preserve cash while advancing CLS-AX and other proprietary ophthalmic candidates through development and regulatory milestones. At the same time, it is trying to expand the platform through additional licensing and collaboration agreements that can generate upfront, milestone and royalty revenue without requiring a large commercial infrastructure. The company is also evaluating strategic alternatives and financing options because its current cash runway is limited.